Organization · Venture Capital
Cross-Border Impact Ventures
Cross-Border Impact Ventures (CBIV) is an impact venture capital firm based in Toronto, Canada, focusing on health technology investments that improve outcomes for women, children, and adolescents globally.
Overview
What Cross-Border Impact Ventures does
What Cross-Border Impact Ventures is
Cross-Border Impact Ventures (CBIV) is an impact venture capital firm based in Toronto, Canada, focusing on health technology investments that improve outcomes for women, children, and adolescents globally.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Venture Capital
- Founded
- Founded in 2021
- Approximate age
- About 5 years
- Structured capabilities
- Funder
- Last reviewed
- March 31, 2026
Official channels
Find Cross-Border Impact Ventures elsewhere
Open the official website or a supported primary organization account.
Capability profile
Cross-Border Impact Ventures as a funder
Investment thesis
Cross-Border Impact Ventures focuses on health technology investments that improve health outcomes for women, children, and adolescents globally, particularly in low- and middle-income countries.
Focus narrative
The firm invests in companies developing medical devices, diagnostics, therapeutics, and digital health innovations. Key focus areas include sexual and reproductive health, maternal and child health, chronic diseases, and health software infrastructure. Cross-Border Impact Ventures targets investments in North America and Europe while also seeking opportunities in low- and middle-income countries.
Value beyond capital
Cross-Border Impact Ventures provides strategic support to portfolio companies, leveraging its expertise in health technology and impact metrics to drive both social and financial returns. The firm emphasizes cross-border commercialization and scalability, particularly in emerging markets, enhancing the growth potential of its investments.
Terms and economics
- Typical check
- $1,000,000–$5,000,000
- Sweet spot
- $3,000,000
Focus and fit
- Stages
- Seed · Series A · Series B · Growth Equity
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 8
Portfolio context
Notable portfolio companies include: Pendulum: AI-driven health infrastructure software optimizing healthcare supply chains. Raydiant Oximetry: Non-invasive fetal monitoring technology to prevent postpartum hemorrhage. Sonio: AI-enhanced fetal ultrasound software for diagnosing pregnancy complications. OncoLens: Digital health platform for oncology care management. mOm Incubators: Low-cost, portable incubators for newborns. Daye: Femtech company offering innovative gynecological health products. Axena Health: Device for treating urinary and fecal incontinence in women. Oxford Cancer Analytics: Biomarker discovery platform for cancer detection.
Common questions
What to know about Cross-Border Impact Ventures
Upseed classifies Cross-Border Impact Ventures under the Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
March 31, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.